Cai X, Garen A
Department of Molecular Biophysics, Yale University, New Haven, CT 06520-8114, USA.
Proc Natl Acad Sci U S A. 1996 Jun 25;93(13):6280-5. doi: 10.1073/pnas.93.13.6280.
The human antimelanoma antibody V86 was cloned from a single-chain Fv molecule (scFv) fusion phage library displaying the heavy chain variable domain (VH) and light chain variable domain (VL.) repertoire of a melanoma patient immunized with genetically-modified autologous tumor cells. Previous ELISA tests for binding of the V86 fusion phage to a panel of human metastatic melanoma and carcinoma cell lines and primary cultures of normal melanocytes, endothelial, and fibroblast cells showed that measurable binding occurred only to the melanoma cells. In this communication, the strict specificity of V86 for melanoma cells was confirmed by immunohistochemical staining tests with cultured cells and frozen tissue sections. The V86 fusion phage stained melanoma cell lines but did not stain carcinoma cell lines or cultured normal cells; V86 also stained specifically the melanoma cells in sections of metastatic tissue but did not stain any of the cells in sections from normal skin, lung, and kidney or from metastatic colon and ovarian carcinomas and a benign nevus. An unexpected finding is that V86 contains a complete VH domain but only a short segment of a VL, domain, which terminates before the CDR1 region. This VL deletion resulted from the occurrence in the VL cDNA of a restriction site, which was cleaved during construction of the scFv library. Thus V86 is essentially a VH antibody. The effect of adding a VI. domain to V86 was examined by constructing scFv fusion phage libraries in which V86 was coupled to Vlambda or Vkappa domains from the original scFv library of the melanoma patient and then panning the libraries against melanoma cells to enrich for the highest affinity antibody clones. None of the V86-Vlambda clones showed significant binding to melanoma cells in ELISA tests; although binding occurred with most of the V86-Vkappa clones, it was generally weaker than the binding of V86. These results indicate that most of the VL domains in the original scFv library reduce or eliminate the affinity of V86 for melanoma cells. Accordingly, VH libraries could provide access to anti-tumor antibodies that might not be detected in scFv or Fab libraries because of the incompatibility of most randomly paired VH and VL, domains.
人抗黑色素瘤抗体V86是从一个展示经基因改造的自体肿瘤细胞免疫的黑色素瘤患者重链可变区(VH)和轻链可变区(VL)全套序列的单链Fv分子(scFv)融合噬菌体文库中克隆得到的。先前的ELISA试验检测V86融合噬菌体与一组人转移性黑色素瘤和癌细胞系以及正常黑素细胞、内皮细胞和成纤维细胞原代培养物的结合情况,结果显示仅与黑色素瘤细胞发生了可检测到的结合。在本报告中,通过对培养细胞和冷冻组织切片进行免疫组织化学染色试验,证实了V86对黑色素瘤细胞具有严格的特异性。V86融合噬菌体可对黑色素瘤细胞系进行染色,但不对癌细胞系或培养的正常细胞染色;V86还可特异性地对转移组织切片中的黑色素瘤细胞进行染色,但不对正常皮肤、肺、肾、转移结肠癌和卵巢癌以及良性痣的切片中的任何细胞进行染色。一个意外的发现是,V86包含一个完整的VH结构域,但仅包含VL结构域的一小段,该小段在CDR1区域之前终止。这种VL缺失是由于VL cDNA中出现了一个限制性酶切位点,该位点在scFv文库构建过程中被切割。因此,V86本质上是一种VH抗体。通过构建scFv融合噬菌体文库来研究给V86添加一个VL结构域的效果,在该文库中,V86与黑色素瘤患者原始scFv文库中的Vλ或Vκ结构域偶联,然后用黑色素瘤细胞对文库进行淘选,以富集具有最高亲和力的抗体克隆。在ELISA试验中,没有一个V86-Vλ克隆显示出与黑色素瘤细胞有显著结合;虽然大多数V86-Vκ克隆发生了结合,但通常比V86的结合弱。这些结果表明,原始scFv文库中的大多数VL结构域会降低或消除V86对黑色素瘤细胞的亲和力。因此,VH文库可能提供获得抗肿瘤抗体(由于大多数随机配对的VH和VL结构域不兼容,这些抗体在scFv或Fab文库中可能无法检测到)的途径。